Effects of Paclitaxel and Docetaxel on EGFR-Expressing Human Carcinoma Cells Under Normoxic Versus Hypoxic Conditions In Vitro

REFERENCES

• Choy H. Taxanes in combined modality therapy for solid tumors. Oncology 1999; 13: 23–38.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Vermorken JB. The taxoids: Comparative clinical pharmacology and therapeutical poten-tial. Drugs 1998; 55: 5–30.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist 2000; 5: 199–208.
   PubMedGoogle Scholar
• Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low con-centrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816–825.
   PubMed Web of Science ®Google Scholar
• Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995; 22: 3–16.
   Web of Science ®Google Scholar
• Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters II. Role of oxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995; 55: 3564–3568.
   PubMed Web of Science ®Google Scholar
• Milas L, Hunter N, Mason KA, Milross C, Peters Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol 1995; 43 (3): 409–412.
   Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408–1416.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987–989.
   PubMed Web of Science ®Google Scholar
• Yuan J, Glazer PM. Mutagenesis induced by the tumor microenvironment. Mutat Res 1998; 400: 439–446.
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Masui H. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327–1333.
   PubMed Web of Science ®Google Scholar
• Fan Z., Baselga J, Masui H. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-4642.
   Google Scholar
• Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989; 9: 1537–1547.
   PubMed Web of Science ®Google Scholar
• Libermann TA, Nusbaum HR, Razon N, Kris R, Schlessinger J. Amplification, enhanced expression, and possi-ble rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985; 313: 144–147.
   PubMed Web of Science ®Google Scholar
• Nishi H, Nishi KH, Johnson AC. Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002; 62: 827–834.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Tosaka A, Takeuchi S, Kobayashi N. Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994; 73: 1913–1918.
   PubMed Web of Science ®Google Scholar
• Montgomery BR, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters b-tubulin isotype expression. J Biol Chem 2000, 275 (23): 17358–17363.
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Godwiwin AK, et al. Frequent expression of a mutant growth factor receptor in multiple human tumors. Cancer Res 1995; 55: 5536.
   PubMed Web of Science ®Google Scholar
• Laderoute KR, Grant TD, Murphy BJ, Sutherland RM. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int J Cancer 1992; 52 (3): 428–432.
   PubMed Web of Science ®Google Scholar
• Aapro M. The scientific rationale for developing tax-olds. Anticancer Drugs 1996; 7 Suppl 2: 33–36.
   PubMedGoogle Scholar
• Garcia P, Braguer D, Caries G, et al. Comparative effects of taxol and Taxotere on two different human carcino-ma cell lines. Cancer Chemother Pharmacol 1994; 34 (4): 335–343.
   PubMed Web of Science ®Google Scholar
• Untch M, Untch A, Sevin BU, et al. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 1994; 5 (1): 24–30.
   PubMed Web of Science ®Google Scholar
• Zoli W, Flamigni A, Frassineti GL, et al. In vitro activi-ty of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Treat 1995; 34 (1): 63–69.
   PubMed Web of Science ®Google Scholar
• Osawa H, Aiba K, Uno S, et al. Multi-drug resistant breast cancer responding to chemotherapy with docetaxel (tax-otere: TXT) Gan To Kagaku Ryoho 1999; 26 (9): 1329-1333.
   Google Scholar
• Giaccia AJ, Koumenis C, Denko N. The influence of tumor hypoxia on malignant progression. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia. Stuttgart: WVG. 1999: 115-124.
   Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58–65.
   PubMed Web of Science ®Google Scholar
• Lin CR, Chen WS, Kruiger W. Expression cloning of human EGF receptor complementary DNA: Gene amplifica-tion and three related messenger RNA products in A431 cells. Science 1984; 224: 843–848.
   PubMed Web of Science ®Google Scholar
• Merlino GT, Xu Y-H, Ishii S, et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984; 224: 417–419.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Coussens L, Hayflick JS. Human epidermal growth factor receptor cDNA sequence and aberrant expres-sion of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418–425.
   PubMed Web of Science ®Google Scholar
• Yoo GH, Piechocki MP, Ensley JF, et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 2002; 8: 3910–3921.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Mendelsohn J. Growth factor receptors as a target for therapy. In: Roth JA, Cox JD, Hong WK, eds. Lung cancer. Cambridge: Blackwell. 1998: 309.
   Google Scholar
• Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002; 62: 1935–1938.
   PubMed Web of Science ®Google Scholar
• Schimke RT, Kung A, Sherwood SS, Sheridan J, Sharma R. Life, death and genomic change in pertubed cell cycles. Phylos Trans R Soc Lond B Biol Sci 1994; 345: 311–317.
   PubMed Web of Science ®Google Scholar